Posted by Michael Wonder on 13 May 2024
Zai Lab announces approval of Augtyro (repotrectinib) for patients with ROS1 positive NSCLC by China’s NMPA
12 May 2024 - The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro achieved a high response rate and durable responses, including robust intracranial responses.
Zai Lab today announced that the National Medical Products Administration in China has approved the new drug application for Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1 positive non-small-cell lung cancer.
